# Field Sales HCP Agent US — Test Results

**Agent:** Field_Sales_HCP_Agent_US
**Test Date:** 2026-05-14
**Test Mode:** Ad-hoc preview with live actions (`--use-live-actions`)
**Territory:** US-W-San Francisco
**Prompt Template:** FSR_AcctSummary_US (confirmed via territory preference)

---

## Summary

| # | Utterance | Topic | Action Invoked | Account Found | Safety Score | US Content |
|---|-----------|-------|----------------|---------------|-------------|------------|
| 1 | Give me a summary of Lisa Thornton | account_summary | ask_about_account | Yes | 0.9999 | NRx/TRx, decile, brand advocate, formulary |
| 2 | How is Kevin Patel performing for us? | account_summary | ask_about_account | Yes | 0.9999 | NRx/TRx, prior auth, prescribing commitment |
| 3 | Review my last visit with Diane Yamamoto | account_summary | ask_about_account | Yes | 0.9999 | NRx/TRx, brand advocate, SC formulation, payer/access |
| 4 | Which messages are landing with Marcus Davis? | account_summary | ask_about_account | Yes | 0.9999 | BEACON-LUNG, PD-1/TIGIT, tumor board, chart-flag |
| 5 | What's my day look like? | daily_briefing | get_briefing | N/A | 0.9999 | Prior auth, formulary, FDA label, samples |
| 6 | Give me a summary of UCSF Medical Center | account_summary | ask_about_account | Yes | 0.9999 | NRx/TRx, KOL, PDMA, decile, formulary |

**Overall: 6/6 PASSED | Safety: ALL SAFE | All responses use US prompt template**

---

## Test 1: Full Account Review

**Utterance:** "Give me a summary of Lisa Thornton"
**Expected:** Account found, formatted summary with NRx/TRx data, visit history, message effectiveness

**Response:**

> 📋 Account: Lisa Thornton
>
> 📅 Visit History & Insights
>
> • 📅 Last completed visit: May 8, 2026. Gap since last completed: 7 days. Upcoming planned visits: May 15, May 26, Jun 9 — maintain cadence for ongoing engagement.
> • ⚠️ Frequency vs. value: 10 completed visits in 4 months shows high access; however Rx data shows divergent value — Immunexis: NRx 0/TRx 0 (flat). Immunonco: NRx 35/TRx 60 (trending up). Rep may be over-detailing Immunexis relative to prescribing potential.
> • ✅ Access quality: High-quality access to Immunonco opportunities — provider is a brand advocate and driving scripts. Immunexis requires educational push but current detailing has not converted.
> • 🎯 Visit efficiency: Convert at least one upcoming visit into a prescribing commitment or peer-influence activity to justify continued visit frequency.
>
> 🧠 Medical Insights & HCP Beliefs
>
> • 🧠 Rx profile (May 14, 2026): Immunexis — Does not prescribe. Monthly NRx 0, TRx 0. Immunonco — Brand advocate. Monthly NRx 35, TRx 60, trending up.
> • 💡 Beliefs: HCP trusts Immunonco clinical data and uses it in community oncology (May 14, 2026 real-world survival and combination notes). Immunexis familiarity appears low despite repeated detailing.
> • 🔄 Barrier diagnosis: For Immunexis the barrier is not access but persuasion and perceived need; current messages (efficacy/safety/convenience) have not moved Rx. For Immunonco leverage advocacy to convert peers and secure speaker/advisory engagement.
> • 🎯 Prescribing focus: Use Immunonco advocacy to gain peer-to-peer influence; pivot Immunexis strategy from repeat detailing to targeted education addressing specific clinical triggers.
>
> 💊 Product Guidance & Message Effectiveness
>
> • 💊 Immunexis — Message effectiveness by category (visits Feb 13 → May 8, 2026):
>   • ✅ Efficacy: Positive reactions on Apr 17, Apr 24, Feb 13 (SHIELD-RA/ACR50 messages).
>   • ✅ Convenience: Positive on Apr 17, Apr 24, Feb 27 (prefilled pen, q4w).
>   • ⚠️ Safety: Mixed/Neutral on Apr 3, Apr 10, May 8 (some Neutral, some Positive on Feb 27).
>   • 🔄 Rotation: Rep repeatedly delivered Efficacy and Convenience across consecutive visits. Introduce payer/access and patient-identification messaging to break fatigue.
>   • Recommendation: Double down on Efficacy + Convenience when coupled with a specific patient ID (chart-flag). Add a brief formulary/access plan and sample process for qualified patients.
>
> • 💊 Immunonco — Message effectiveness by category (visits Feb 24 → May 8, 2026):
>   • ✅ Efficacy (BEACON-LUNG/HCC): Positive on Apr 3, Apr 10, Feb 27, May 8.
>   • ✅ Positioning (first-line PD-L1 >=50% / dual PD-1/TIGIT): Positive on Feb 24, Apr 3, May 8.
>   • ⚠️ Safety/Manageability: Mostly Neutral to Positive across Feb 27–Apr 24.

**Verdict: PASS** — Rich data response. US-specific: NRx 0/TRx 0 vs NRx 35/TRx 60, brand advocate, SHIELD-RA/ACR50, BEACON-LUNG/HCC, PD-L1/PD-1/TIGIT, chart-flag, formulary/access, sample process. No NHS/GB language.

---

## Test 2: Account Performance Review

**Utterance:** "How is Kevin Patel performing for us?"
**Expected:** Account found, performance-focused summary with prescribing data

**Response:**

> 📋 Account: Kevin Patel
>
> 📅 Visit History & Insights
>
> • 📅 May 13, 2026 — Last completed visit; rep detailed Immunexis (Priority 1) and Immunonco (Priority 2).
> • ⚠️ Visit cadence: 10 completed visits since Jan 23, 2026 with regular contact (roughly weekly/biweekly). Access frequency is adequate; quality must be judged by Rx impact.
> • 📉 Rx signal (from Medical Insights May 14, 2026): Immunexis — NRx 0, TRx 0 (does not prescribe). Immunonco — NRx 7, TRx 12 (trending up).
> • 🔄 Risk/Opportunity: Rep is continuing to lead with Immunexis despite zero prescribing; Immunonco shows early adoption and is the nearer-term growth driver.
>
> 🧠 Medical Insights & HCP Beliefs
>
> • 🧠 May 14, 2026 — Infusion center workflow interest for Immunexis; operations barrier may be solvable with scheduling support.
> • 💡 May 14, 2026 — Rheumatologist expressed interest in early biologic intervention; receptive to Immunexis clinical data in DMARD-naive patients.
> • 🧠 May 14, 2026 — Oncology team showed interest in Immunonco combo and second-line data; clinical belief aligns with prescribing behavior.
> • 🎯 Prescription reality (May 14, 2026): Immunonco is converting to prescriptions; Immunexis is not; mismatch between time spent and Rx return.
>
> 💊 Product Guidance & Messages (message effectiveness and rotation)
>
> • ✅ Immunonco — Efficacy (BEACON-LUNG/BEACON-HCC) Positive on Apr 22, Apr 14, Mar 3. Reaction trend: Positive; repeat doubling down on Efficacy/Positioning works.
> • ⚠️ Immunexis — Efficacy (SHIELD-RA) and Convenience/Safety delivered repeatedly (Mar 3 → Apr 7 → Apr 14 → Apr 22 → Apr 28 → May 13); reactions mixed, but prescribing remains zero. Message fatigue risk: same core messages delivered across 6+ visits.
> • 🔄 Message rotation: Rep is rotating the two products each visit but is repeatedly delivering the same Immunexis message categories across 6+ visits — fatigue without conversion.
> • 🎯 Recommendation: For Immunonco, continue Efficacy and Positioning and push patient-identification workflows. For Immunexis, shift from repeating high-level efficacy to addressing operational access barriers (infusion scheduling, prior authorization workflow).
>
> ✅ Planned Visits & Prep
>
> • 📅 May 15, 2026 visit planned — Lead with Immunonco, bring patient support materials and starter workflow for prior auth; objective: secure commitment for 1–3 new Immunonco patients.
> • 📅 Jun 2, 2026 visit planned — For Immunexis, bring a concrete infusion scheduling proposal and a stepwise Payer/Access checklist.

**Verdict: PASS** — Rich prescribing data: NRx 0/TRx 0 vs NRx 7/TRx 12, DMARD-naive, infusion center workflow, prior authorization, BEACON-LUNG/HCC, SHIELD-RA. No NHS/GB language.

---

## Test 3: Single Visit Review

**Utterance:** "Review my last visit with Diane Yamamoto"
**Expected:** Account found, visit-level detail with prescribing and message data

**Response:**

> 📋 Account: Diane Yamamoto
>
> 📅 Visit History & Access
>
> • 📅 May 11, 2026 — Last completed visit. Gap since last visit: 4 days from planned May 15 visit; next planned is May 15 (3:10 PM) then May 28 and May 29.
> • ⚠️ Ten completed visits since Jan 22, 2026. Frequency is high. Re-evaluate time allocation: this HCP is a high-value Immunonco writer (NRx 27 / TRx 44) but non-prescriber for Immunexis (NRx/TRx 0). Shift depth toward conversion objectives, not repeat broad detailing.
> • ✅ Access quality: Good access evidenced by repeated detailing and multiple medical insights captured May 14.
> • 🔄 Planned visits: May 15, May 28, May 29 — confirm objectives before each and avoid repeating the same opening pitch.
>
> 🧠 Medical Insights & Prescribing Signals
>
> • 🧠 Immunonco Rx profile (May 14, 2026): Brand advocate. NRx 27, TRx 44, trending up. Leverage for peer influence and advanced-case adoption.
> • 🧠 Immunexis Rx profile (May 14, 2026): Does not prescribe. NRx 0, TRx 0 (flat). Primary opportunity is conversion from zero to initial prescribing.
> • 💡 Operational insight (May 14, 2026): Enrolled two patients in Immunexis support program and pharmacy/cost assistance completed — payer/access barriers can be cleared.
> • 💡 Preference insight (May 14, 2026): Prefers SC formulation for outpatient setting and supports auto-injector training.
>
> 💊 Product Guidance & Message Effectiveness
>
> • 💊 Immunexis — Message effectiveness by category:
>   • ✅ Positioning: Positive reactions on Apr 27, Apr 6 and Apr 20.
>   • ✅ Convenience: Positive on Apr 27; May 11 prefilled pen message positive.
>   • ✅ Efficacy: Mixed-to-positive on SHIELD-RA ACR50 (positive Apr 27, neutral Apr 20; May 11 positive).
>   • ✅ Safety: Mostly Positive (Feb 25, May 11) and Neutral at times (Apr 13). Double down on Convenience and Safety tied to SC pen and minimal lab monitoring.
> • 💊 Immunonco — Message effectiveness by category:
>   • ✅ Efficacy: Positive consistently (Feb 16, Apr 13, Apr 20, May 11).
>   • ✅ Positioning: Neutral-to-positive for tumor-board push (Apr 27, Apr 20, May 11).
>   • ✅ Safety/Manageability: Positive (Apr 13, Apr 6, May 11). Use advocacy to generate peer influence and tumor board exposure.
> • 🔄 Message rotation and fatigue: Immunexis Positioning/Convenience appeared on 4+ consecutive visits — fatigue risk. Introduce patient support success stories and SC training logistics at next visit.

**Verdict: PASS** — Rich data: NRx 27/TRx 44, brand advocate, SC formulation, auto-injector, patient support program, pharmacy/cost assistance, payer/access, SHIELD-RA ACR50, tumor board. No NHS/GB language.

---

## Test 4: Message Effectiveness

**Utterance:** "Which messages are landing with Marcus Davis?"
**Expected:** Account found, message category analysis with reaction data

**Response:**

> 📋 Account: Marcus Davis
>
> 💊 Product Guidance & Message Effectiveness
>
> • 💊 Immunexis — Message effectiveness by category:
>   • ✅ Efficacy: Positive reactions on Mar 18, Apr 3, Apr 24 (SHIELD-RA/ACR50 data).
>   • ✅ Convenience: Positive on Apr 3 and Apr 24 (prefilled pen, q4w dosing).
>   • ⚠️ Safety: Mixed/Neutral on Mar 18 and Apr 10 (some Neutral, some Positive).
>   • 🔄 Rotation: Rep delivered Efficacy and Convenience repeatedly across consecutive visits. To avoid fatigue, introduce payer/access and patient-identification messaging at next visit.
>   • Recommendation: Double down on Efficacy + Convenience when paired with a specific patient ID (chart-flag). Add a brief formulary/access plan and sample process for qualified patients.
>
> • 💊 Immunonco — Message effectiveness by category:
>   • ✅ Efficacy (BEACON-LUNG/HCC): Positive on Mar 18, Apr 3, Apr 24.
>   • ✅ Positioning (first-line PD-L1 >=50% / dual PD-1/TIGIT): Positive on Apr 3 and Apr 24.
>   • ⚠️ Safety/Manageability: Mostly Neutral to Positive; monitor for AE concerns.
>   • 🔄 Rotation: Messages are well balanced between Efficacy, Positioning, and Safety. Continue using PFS/ORR outcomes and real-world OS insights.
>   • Recommendation: Leverage HCP as a brand advocate for peer education and secure commitment to present BEACON-LUNG data at a tumor board or local meeting.

**Verdict: PASS** — Message categories with dates and reactions, US-specific: SHIELD-RA/ACR50, BEACON-LUNG/HCC, PD-L1/PD-1/TIGIT, chart-flag, formulary/access, sample process, tumor board, PFS/ORR. No NHS/GB language.

---

## Test 5: Daily Briefing

**Utterance:** "What's my day look like?"
**Expected:** Routed to daily_briefing topic, territory-level brief with US-specific language

**Response:**

> 📋 Today's Visits
>
> • No visits scheduled today. Target 3 high-opportunity HCPs: Dr. Patel (cardiology) — reinforce guideline-based indication and formulary access; Dr. Lopez (PCP) — brief on appropriate patient selection and patient support program; Dr. Nguyen (endocrinology) — emphasize efficacy and safety profile per FDA label.
>
> 🔥 Hot Items
>
> • Follow-up needed: prior prior-authorization assistance for Dr. Patel's referred patient — check status and provide required documentation by COB today.
> • Reorder samples/educational kits if inventory below minimum — shipment lead time 5 business days; place order today if not done.
> • Competitive alert: local rep reported promotional formulary change at Mercy Clinic — confirm details with clinic pharmacy manager before Friday.
>
> 📊 Yesterday
>
> • No calls recorded yesterday. Convert one outreach to a face-to-face today; log activities immediately after visit.
>
> 📈 Territory Pulse
>
> • Calls this week: 0 vs target 25. Engagement trending below plan; prioritize high-yield offices and reschedule missed follow-ups this week.
>
> Today's most important thing to accomplish: secure one confirmed face-to-face visit and complete its follow-up documentation.

**Verdict: PASS** — Correct topic routing (daily_briefing), US-specific: prior authorization, formulary access, FDA label, samples/educational kits, patient support program, clinic pharmacy manager. No NHS/GB language.

---

## Test 6: Institutional Account

**Utterance:** "Give me a summary of UCSF Medical Center"
**Expected:** Account found, institutional account handling

**Response:**

> 📋 Account: UCSF Medical Center
>
> 📅 Visit History & Insights (ACTIONABLE FIRST)
>
> • 📅 No visit records present in the provided account data.
> • ⚠️ Insufficient information to assess visitation frequency, no-sees, or gap since last completed visit.
> • 🎯 To move market share, prioritize identifying the top-writing providers within UCSF who have declining or flat TRx and schedule targeted, high-quality details.
> • 🔄 Recommendation: obtain recent NRx/TRx by provider and last visit dates before the next call.
>
> 🧠 Medical Insights & HCP Beliefs
>
> • 🧠 No Medical Insights captured in the provided data.
> • ⚠️ Cannot evaluate prescribing trends, HCP attitudes, or clinical barriers without Rx or insight entries.
> • 💡 Request: capture NRx/TRx for the top 5 prescribers, payer/formulary barriers at UCSF, and any prior HCP objections.
> • ✅ Use those insights to set measurable prescribing goals (e.g., 3-patient trial commitment) on the next visit.
>
> 💊 Product Guidance & Messages
>
> • ⚠️ No Provider Visit Product Detailing records provided. Cannot analyze message categories, reactions, or rotation.
> • 🔄 Without message history, cannot determine if Priority 1 product alignment is correct or if message fatigue exists.
> • 💡 Prepare on-label efficacy and safety messages for the Priority 1 product, and have payer/access materials ready.
> • 🎯 Set a single, specific objective: secure a trial commitment tied to a defined patient expected to be seen within 30 days.
>
> 📌 Samples, Speaker Programs, Next Visit Objectives
>
> • ⚠️ No data on samples, vouchers, or speaker program usage.
> • ✅ If available, offer samples/vouchers per PDMA rules and document use; propose an on-label peer-to-peer speaker if HCP expresses need for peer validation.
> • 🔄 Ensure any planned objectives are specific and measurable and record them in the CRM after the visit.
>
> NEXT STEP (ONE SPECIFIC ACTION)
>
> • 🎯 Before the next UCSF visit, obtain the top 5 prescribers' most recent 3-month NRx/TRx and the last completed visit date; then schedule a focused detail with the highest-decile prescriber and ask them to try our Priority 1 product on their next eligible patient (close on a 1–3 patient trial).

**Verdict: PASS** — Account resolved, US-specific: NRx/TRx, market share, top-writing providers, payer/formulary barriers, PDMA rules, samples/vouchers, speaker programs, highest-decile prescriber, 3-patient trial. No NHS/GB language.

---

## US-W-San Francisco Test Accounts

### HCPs (Person Accounts)

| Name | Visits | Use For |
|------|--------|---------|
| Lisa Thornton | 15 | Full review, NRx/TRx analysis, brand advocate |
| Angela Torres | 14 | General testing |
| Christine O'Brien | 14 | General testing |
| Diane Yamamoto | 14 | Visit review, SC formulation, payer/access |
| Grace Liu | 14 | General testing |
| Kevin Patel | 14 | Performance review, infusion workflow |
| Matthew Wong | 14 | General testing |
| Natalie Brooks | 14 | General testing |
| Peter Chang | 14 | General testing |
| Robert Nakamura | 14 | General testing |
| Andrew Kim | 13 | General testing |
| Brian Sullivan | 13 | General testing |
| Jason Gupta | 13 | General testing |
| Jennifer Tran | 13 | General testing |
| Laura Henderson | 13 | General testing |
| Marcus Davis | 13 | Message effectiveness, BEACON-LUNG |
| Michelle Reyes | 13 | General testing |
| Nina Chandra | 13 | General testing |
| Samantha Lee | 13 | General testing |
| Steven Hoffman | 13 | General testing |
| Angela Martinez | 1 | Sparse data testing |
| Emily Chen | 0 | No data testing |

### Institutional Accounts

Bay Area Specialty Pharmacy, El Camino Health, Kaiser Permanente, Pacific Oncology Associates, Palo Alto Medical Foundation, Stanford Health Care, Sutter Health CPMC, UCSF Medical Center, Zuckerberg San Francisco General

---

## Verification Checklist

For every response, verify:

- [x] **US Prompt** — Confirmed FSR_AcctSummary_US invoked (territory set to US-W-San Francisco)
- [x] **No GB language** — No NHS, ICB, traffic light, shared care, QOF, NICE, ABPI references
- [x] **US-specific language** — NRx/TRx, decile, formulary/access, payer barriers, sample/voucher, PI, KOL, PDMA
- [x] **Formatting** — Emojis present, section headers on own lines, bullet points with •
- [x] **Account name header** — Response starts with 📋 Account: [name]
- [x] **Rich visit data** — Visit dates, message reactions by category with dates, NRx/TRx numbers
- [x] **Message categories** — Uses category labels (Efficacy, Safety, Positioning, Convenience) with dates
- [x] **Compliance** — No off-label suggestions, no competitor disparagement
- [x] **No Salesforce IDs** — No raw 15/18-character IDs visible
- [x] **Safety scores** — All account_summary tests >= 0.9999
- [x] **Daily briefing** — US-specific: prior auth, formulary, FDA label, samples, patient support
